Company intelligence / Profile preview

DelSite

Irving, Texas, USA

Ownership: Private
Development stage: Other

Overview

DelSite Biotechnologies was a specialty pharmaceutical company focused on the development of novel drug delivery systems using its proprietary GelSite technology. The GelSite platform utilized a pH-sensitive, in situ gelling polysaccharide to provide controlled release and enhanced delivery of vaccines, proteins, and peptides. The company's primary product candidate was the GelVac nasal powder vaccine delivery system, which was evaluated in clinical trials for H5N1 influenza. DelSite was a wholly-owned subsidiary of Carrington Laboratories and ceased operations after its parent company filed for bankruptcy in 2009.

Therapeutic areas: EndocrinologyInfectious Diseases
Modalities: Hydrogel-based drug delivery therapyVaccineProteinPeptides
Industry: Biotech

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID)

Beyond the preview

Go deeper on DelSite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DelSite.

Explore the full profile